Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings from the Phase III DREAMS-2 study on its drug candidate mazdutide at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD). Mazdutide, a dual agonist targeting the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), has shown superior efficacy compared to dulaglutide in managing glycemic control and reducing body weight in Chinese adults with type 2 diabetes (T2D). The study also indicated that mazdutide has a positive impact on multiple cardiometabolic risk factors, such as blood pressure, lipid profiles, serum uric acid, and liver enzymes.
Innovent has secured an exclusive license agreement with Eli Lilly and Company, a leading pharmaceutical corporation in the U.S., for the development and potential commercialization of OXM3, also known as mazdutide, in China. The company is currently awaiting regulatory decisions in China for two key indications: chronic weight management in adults with obesity or overweight, and glycemic control in adults with type 2 diabetes. – Flcube.com
